Treatment of Cancer-Associated Venous Thrombosis

REFERENCES

• Blom J. W., Doggen C. J. M., Osanto S., Rosendaal F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA Feb 9, 2005; 293(6)715–722
   PubMed Web of Science ®Google Scholar
• Silverstein M. D., Heit J. A., Mohr D. N., Petterson T. M., O'Fallon W. M., Melton L. J., III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med Mar 23, 1998; 158(6)585–593
   PubMed Web of Science ®Google Scholar
• Heit J. A., Silverstein M. D., Mohr D. N., Petterson T. M., O'Fallon W. M., Melton L. J., III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med Mar 27, 2000; 160(6)809–815
   PubMed Web of Science ®Google Scholar
• Stein P. D., Beemath A., Meyers F. A., Skaf E., Sanchez J., Olson R. E. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med Jan, 2006; 119(1)60–68
   PubMed Web of Science ®Google Scholar
• Otten H. M., Mathijssen J., Ten Cate H., Soesan M., Inghels M., Richel D. J., et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med Jan 26, 2004; 164(2)190–194
   PubMed Web of Science ®Google Scholar
• Ambrus J. L., Ambrus C. M., Mink I. B., Pickren J. W. Causes of death in cancer patients. J Med 1975; 6(1)61–64
   PubMedGoogle Scholar
• Rickles F. R., Edwards R. L. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood Jul 1, 1983; 62(1)14–31
   PubMed Web of Science ®Google Scholar
• Sorensen H. T., Mellemkjar L., Olsen J. H., Baron J. A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med Dec 21, 2000; 343(25)1846–1850
   PubMed Web of Science ®Google Scholar
• Otten H. M. Thrombosis and Cancer. thesis, Academic Medical Center, University of Amsterdam, the Netherlands 2002
   Google Scholar
• Bouillaud S. De l'Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch Generales de Med 1823; 1: 188–204
   Google Scholar
• Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood Sep 15, 2007; 110(6)1723–1729
   PubMed Web of Science ®Google Scholar
• Trousseau A. Phlegmasia alba dolens. Clinique medicinale de l'Hotel-Dieu de Paris. Bailliere J.-B. et fils, Paris 1865; 645–712
   Google Scholar
• Khorana A. A. Malignancy, thrombosis and trousseau: the case for an eponym. J Thromb Haemost Dec 3, 2003; 1(12)2463–2465
   PubMed Web of Science ®Google Scholar
• Homans J. Venous thrombosis in the lower limbs: its relation to pulmonary embolism. Am J Surg Nov, 1937; 38(2)316–326
   Google Scholar
• Basu D., Gallus A., Hirsh J., Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med Aug 17, 1972; 287(7)324–327
   PubMed Web of Science ®Google Scholar
• Murray G. D., Best C. H. The use of heparin in thrombosis. Ann Surg Aug, 1938; 108(2)163–177
   PubMedGoogle Scholar
• Bauer G. The introduction of heparin therapy in cases of early thrombosis. Circulation Jan 1, 1959; 19(1)108–109
   PubMed Web of Science ®Google Scholar
• Griminger P. Vitamin K antagonists: the first 50 years. J Nutr Jul 1, 1987; 117(7)1325–1329
   PubMed Web of Science ®Google Scholar
• Barritt D W, Jordan S C. Anticoagulant treatment drugs in the treatment of pulmonary embolism: a controlled trail. The Lancet Jun 18, 1960; 275(7138)1309–1312
   Google Scholar
• Brandjes D. P., Heijboer H., Buller H. R., de Rijk M., Jagt H., ten Cate J. W. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med Nov 19, 1992; 327(21)1485–1489
   PubMed Web of Science ®Google Scholar
• Kearon C., Ginsberg J. S., Kovacs M. J., Anderson D. R., Wells P., Julian J. A., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med Aug 14, 2003; 349(7)631–639
   PubMed Web of Science ®Google Scholar
• Prins M. H., Hutten B. A., Koopman M. M., Buller H. R. Long-term treatment of venous thromboembolic disease. Thromb Haemost Aug, 1999; 82(2)892–898
   PubMed Web of Science ®Google Scholar
• Buller H. R., Prins M. H. Secondary prophylaxis with warfarin for venous thromboembolism. N Engl J Med Aug 14, 2003; 349(7)702–704
   PubMed Web of Science ®Google Scholar
• Buller H. R., Sohne M., Middeldorp S. Treatment of venous thromboembolism. J Thromb Haemost Aug 21, 2005; 3(8)1554–1560
   PubMed Web of Science ®Google Scholar
• Kearon C., Kahn S. R., Agnelli G., Goldhaber S., Raskob G. E., Comerota A. J. Antithrombotic therapy for venous thromboembolic disease: American College of chest physicians evidence-based clinical practice guidelines (8th edition). Chest Jun 1, 2008; 133(Suppl. 6)454S–545
   PubMed Web of Science ®Google Scholar
• Hull R. D., Raskob G. E., Pineo G. F., Green D., Trowbridge A. A., Elliott C. G., et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med Apr 9, 1992; 326(15)975–982
   PubMed Web of Science ®Google Scholar
• Koopman M. M. W., Prandoni P., Piovella F., Ockelford P. A., Brandjes D. P. M., van der Meer J., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med Mar 14, 1996; 334(11)682–687
   PubMed Web of Science ®Google Scholar
• Buller H. R., Agnelli G., Hull R. D., Hyers T. M., Prins M. H., Raskob G. E. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest Sep 1, 2004; 126(Suppl. 3)401S–428S
   PubMed Web of Science ®Google Scholar
• Lee A., Levine M. Treatment of venous thromboembolism in cancer patients. Cancer Control Sep, 2005; 12(Suppl. 1)17–21
   PubMedGoogle Scholar
• Hutten B. A., Prins M. H., Gent M., Ginsberg J., Tijssen J. G. P., Buller H. R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol Sep 17, 2000; 18(17)3078–3083
   PubMed Web of Science ®Google Scholar
• Wester J. P., de Valk H. W., Nieuwenhuis H. K., Brouwer C. B., van der G. Y., Meuwissen O. J., et al. Risk factors for bleeding during treatment of acute venous thromboembolism. Thromb Haemost Nov, 1996; 76(5)682–688
   PubMed Web of Science ®Google Scholar
• Kuijer P. M. M., Hutten B. A., Prins M. H., Buller H. R. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med Mar 8, 1999; 159(5)457–460
   PubMed Web of Science ®Google Scholar
• Palareti G., Legnani C., Lee A., Manotti C., Hirsh J., D'Angelo A., et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost Nov, 2000; 84(5)805–810
   PubMed Web of Science ®Google Scholar
• Prandoni P., Lensing A. W. A., Piccioli A., Bernardi E., Simioni P., Girolami B., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood Nov 15, 2002; 100(10)3484–3488
   PubMed Web of Science ®Google Scholar
• Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., Hylek E. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest Sep 1, 2004; 126(Suppl. 3)204S–233S
   PubMedGoogle Scholar
• Bona R. D., Sivjee K. Y., Hickey A. D., Wallace D. M., Wajcs S. B. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost Oct, 1995; 74(4)1055–1058
   PubMed Web of Science ®Google Scholar
• Kakkar V. V. Low-dose heparin to low molecular weight heparin prophylaxis: in pursuit of excellence—a personal perspective. J Thromb Haemost Feb 3, 2005; 3(2)195–209
   PubMed Web of Science ®Google Scholar
• Weitz J. I. Low-molecular-weight heparins. N Engl J Med Sep 4, 1997; 337(10)688–699
   PubMed Web of Science ®Google Scholar
• Kovacs M. J., Levine M. N., Keeney M., Mackinnon K. M., Lee A. Y. Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients. Thromb Haemost Jun, 2005; 93(6)1185–1188
   PubMed Web of Science ®Google Scholar
• Das S. K., Cohen A. T., Edmondson R. A., Melissari E., Kakkar V. V. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg Jun 21, 1996; 20(5)521–527
   PubMed Web of Science ®Google Scholar
• Lee A. Y. Y., Levine M. N., Baker R. I., Bowden C., Kakkar A. K., Prins M., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med Jul 10, 2003; 349(2)146–153
   PubMed Web of Science ®Google Scholar
• Akl E. A., Rohilla S., Barba M., Sperati F., Terrenato I., Muti P., et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008, (1):CD006649. Accessed 23 January 2008
   Web of Science ®Google Scholar
• Akl E., Barba M., Rohilla S., Terrenato I., Sperati F., Muti P., et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008, (2): CD006650. Accessed 16 April 2008
   Web of Science ®Google Scholar
• Mandala M., Falanga A., Roila F. Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations on behalf of the ESMO guidelines working group. Ann Oncol May 1, 2008; 19(Suppl. 2)ii126–ii127
   PubMedGoogle Scholar
• Kolbach D. N., Sandbrink M. W. C., Hamulyak K., Prins M. H., Neumann M. H. A. M. Non-pharmaceutical measures for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev 2003, Iss 3. Art. No.: CD004174. DOI: 10.1002/14651858. CD004174.pub2
   PubMedGoogle Scholar
• Letai A., Kuter D. J. Cancer, coagulation, and anticoagulation. Oncologist Dec 1, 1999; 4(6)443–449
   PubMedGoogle Scholar
• Wells P. S., Anderson D. R., Rodger M. A., Forgie M. A., Florack P., Touchie D., et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med Apr 11, 2005; 165(7)733–738
   PubMed Web of Science ®Google Scholar
• Petralia G., Kakkar A. Treatment of venous thromboembolism in cancer patients. Semin Thromb Hemost 2007; 33(07)707–711
   PubMedGoogle Scholar
• The V an. Gogh Investigators. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med Sep 13, 2007; 357(11)1105–1112
   PubMed Web of Science ®Google Scholar
• The V an. Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med Sep 13, 2007; 357(11)1094–1104
   PubMed Web of Science ®Google Scholar
• The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med Oct 30, 2003; 349(18)1695–1702
   PubMed Web of Science ®Google Scholar
• Prandoni P., Carta M., Cogo A., Ruol A., Vigo M., Casara D., et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet Feb 22, 1992; 339(8791)441–445
   PubMed Web of Science ®Google Scholar
• Hettiarachchi R. J., Smorenburg S. M., Ginsberg J., Levine M., Prins M. H., Buller H. R. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost Aug, 1999; 82(2)947–952
   PubMed Web of Science ®Google Scholar
• Klerk C. P. W., Smorenburg S. M., Otten H. M., Lensing A. W. A., Prins M. H., Piovella F., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol Apr 1, 2005; 23(10)2130–2135
   PubMed Web of Science ®Google Scholar
• Altinbas M., Coskun H. S., Er O., Ozkan M., Eser B., Unal A., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost Aug, 2004; 2(8)1266–1271
   PubMed Web of Science ®Google Scholar
• Kakkar A. K., Levine M. N., Kadziola Z., Lemoine N. R., Low V., Patel H. K., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol May 15, 2004; 22(10)1944–1948
   PubMed Web of Science ®Google Scholar
• Sideras K., Schaefer P. L., Okuno S. H., Sloan J. A., Kutteh L., Fitch T. R., et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc Jun, 2006; 81(6)758–767
   PubMed Web of Science ®Google Scholar
• Buller H. R., van Doormaal F. F., van Sluis G. L., Kamphuisen P. W. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost Jul, 2007; 5(Suppl. 1)246–254
   PubMedGoogle Scholar
• Hull R. D., Pineo G. F., Brant R. F., Mah A. F., Burke N., Dear R., et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med Dec, 2006; 119(12)1062–1072
   PubMed Web of Science ®Google Scholar
• Deitcher S. R., Kessler C. M., Merli G., Rigas J. R., Lyons R. M., Fareed J. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin App Thromb Hemost Oct 1, 2006; 12(4)389–396
   PubMed Web of Science ®Google Scholar
• Meyer G., Marjanovic Z., Valcke J., Lorcerie B., Gruel Y., Solal-Celigny P., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med Aug 12, 2002; 162(15)1729–1735
   PubMed Web of Science ®Google Scholar
• Cesarone M., Ledda A., Belcaro G., Geroulakos G. Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients. Circulation 2003; 108(117), (Suplemment) Abstract 2875
   Google Scholar
• Lopez-Beret P., Orgaz A., Fontcuberta J., Doblas M., Martinez A., Lozano G., et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg Jan, 2001; 33(1)77–90
   PubMed Web of Science ®Google Scholar